Current Report Filing (8-k)
April 22 2016 - 5:26PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): April 22, 2016
THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-32979
|
94-3409596
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
170 Harbor Way, Suite 300
South San Francisco, California 94080
(Address of principal executive offices)(Zip
Code)
(650) 474-8200
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On April 22, 2016, the board of directors
(the “Board”) of Threshold Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating
and Governance Committee of the Board, approved and adopted the following amendments to the Company’s Corporate Governance
Guidelines (“Guidelines”).
The
Guidelines were amended to provide that any nominee for director in an uncontested election who does not receive a majority of
the votes cast (i.e. receives a greater number of votes “withheld” from his or her election than votes “for”
in such election) shall submit his or her offer of resignation for consideration by the Nominating and Governance Committee. The
Nominating and Governance Committee and the Board may consider all of the relevant facts and circumstances in deciding whether
to accept a director’s resignation. The Board shall promptly publicly disclose its decision and an explanation of such decision
regarding the resignation in a filing with the Securities
and Exchange Commission and a press release.
The
amended Guidelines effective April 22, 2016
are
attached as an Exhibit 99.1 to this Form 8-K and are incorporated by reference herein.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
Exhibit 99.1
|
Corporate Governance Guidelines of Threshold Pharmaceuticals as amended effective April 22, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
THRESHOLD PHARMACEUTICALS, INC.
|
|
|
|
|
Date: April 22, 2016
|
By:
|
/s/ Harold E. Selick, Ph.D.
|
|
|
Name:
|
Harold E. Selick, Ph.D.
|
|
|
Title:
|
Chief Executive Officer
|
|
Exhibit Index
Exhibit No.
|
Description
|
|
|
|
|
Exhibit 99.1
|
Corporate Governance Guidelines of Threshold Pharmaceuticals as amended effective April 22, 2016
|
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Sep 2023 to Sep 2024